February 6, 2025 - 17:33
In the fourth quarter of 2024, the company reported a remarkable 45% increase in revenue, reaching $13.53 billion. This surge was primarily fueled by significant volume growth from its flagship products, Mounjaro and Zepbound. The performance in this quarter showcases the company's robust market presence and the effectiveness of its growth strategies.
Additionally, non-incretin revenue experienced a solid 20% increase compared to the same period in 2023, reflecting the company's diverse portfolio and successful expansion into new therapeutic areas. The strong financial results indicate not only the popularity of its current offerings but also the potential for future growth.
Looking ahead, the company has provided guidance for 2025, emphasizing its commitment to innovation and market leadership. With a focus on enhancing product accessibility and exploring new opportunities, the company is well-positioned to sustain its momentum and deliver continued value to stakeholders in the coming year.
